Nonsteroidal aromatase inhibitors: Recent advances

被引:100
|
作者
Recanatini, M [1 ]
Cavalli, A [1 ]
Valenti, P [1 ]
机构
[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
关键词
cytochrome P450; enzyme inhibitors; breast cancer therapy; anti-tumor drugs; steroid hormones;
D O I
10.1002/med.10010
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aromatase is the cytochrome P450 enzyme responsible for the last step of estrogen biosynthesis, and aromatase inhibitors constitute an important class of drugs in clinical use for the treatment of breast cancer. Nonsteroidal aromatase inhibitors (NSAIs) are competitive inhibitors of aromatase, which bind to the enzyme active site by coordinating the iron atom present in the heme group of the P450 protein. Presently, third generation NSAIs are in use, and research efforts are being carried out both to identify new molecules of therapeutic interest and to clarify the mechanism of action. In this article, we present a survey of the compounds that have been recently reported as NSAIs. to provide a broad view on the general structure-activity relationships of the class. Moreover, starting from the current knowledge of the mechanistic aspects of aromatase action and from recent theoretical work on the molecular modeling of both enzyme and inhibitors, we try to indicate a way to integrate these different studies in view of a more general understanding of the aromeatase-inhibitor system. Finally, some aspects regarding the possible future development of the field are considered briefly. (C) 2002 Wiley Periodicals, Inc.
引用
收藏
页码:282 / 304
页数:23
相关论文
共 50 条
  • [21] PATHOGENESIS OF NONSTEROIDAL ANTIINFLAMMATORY DRUG GASTROPATHY - RECENT ADVANCES
    WALLACE, JL
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1993, 5 (06) : 403 - 407
  • [22] Recent advances in aromatase inhibitor therapy for breast cancer
    Assikis, VJ
    Buzdar, A
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 120 - 128
  • [23] Recent advances for FLAP inhibitors
    Pettersen, Daniel
    Davidsson, Ojvind
    Whatling, Carl
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (13) : 2607 - 2612
  • [24] Recent advances in sialidase inhibitors
    Dowle, MD
    Howes, PD
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (11) : 1461 - 1478
  • [25] Farnesyltransferase inhibitors: recent advances
    Huang, CY
    Rokosz, L
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (02) : 175 - 186
  • [26] PYRIDYL-SUBSTITUTED TETRALONE DERIVATIVES - A NEW CLASS OF NONSTEROIDAL AROMATASE INHIBITORS
    BAYER, H
    HARTMANN, RW
    ARCHIV DER PHARMAZIE, 1991, 324 (10) : 815 - 820
  • [27] SEPARATION OF THE ENANTIOMERS OF SOME RACEMIC NONSTEROIDAL AROMATASE INHIBITORS AND BARBITURATES BY CAPILLARY ELECTROPHORESIS
    FRANCOTTE, E
    CHERKAOUI, S
    FAUPEL, M
    CHIRALITY, 1993, 5 (07) : 516 - 526
  • [28] Nonsteroidal and steroidal aromatase inhibitors in breast cancer - The Hamilton/Volm article reviewed
    Buzdar, AU
    ONCOLOGY-NEW YORK, 2001, 15 (08): : 978 - 979
  • [29] Enantioselective nonsteroidal aromatase inhibitors identified through a Multidisciplinary medicinal chemistry approach
    Cavalli, A
    Bisi, A
    Bertucci, C
    Rosini, C
    Paluszcak, A
    Gobbi, S
    Giorgio, E
    Rampa, A
    Belluti, F
    Piazzi, L
    Valenti, P
    Hartmann, RW
    Recanatini, M
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (23) : 7282 - 7289
  • [30] Design, Synthesis, and Structure-Activity Relationships of Azolylmethylpyrroloquinolines as Nonsteroidal Aromatase Inhibitors
    Ferlin, Maria Grazia
    Carta, Davide
    Bortolozzi, Roberta
    Ghodsi, Razieh
    Chimento, Adele
    Pezzi, Vincenzo
    Moro, Stefano
    Hanke, Nina
    Hartmann, Rolf W.
    Basso, Giuseppe
    Viola, Giampietro
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (19) : 7536 - 7551